Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 6, 1997, Pages 557-560

  Webster, Lorraine K ^a   Linsenmeyer, Martha E ^a   Rischin, Danny ^a   Urch, Maureen E ^a   Woodcock, David M ^a   Millward, Michael J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Docetaxel; Etoposide; Multidrug resistance; Polysorbate 80

Indexed keywords

CREMOPHOR; DAUNORUBICIN; DOCETAXEL; ETOPOSIDE; POLYSORBATE 80;

ADULT; ARTICLE; BIOASSAY; BLOOD LEVEL; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DETERMINATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; MALE; MODULATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SOLID TUMOR;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; POLYSORBATES; SURFACE-ACTIVE AGENTS; TAXOIDS;

EID: 0031024553     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050615     Document Type: Article

References (19)

1. Azmin MN, Stuart JFB, Florence AT (1985) The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 14:238-242
2. Bourgeois H, Gruia G, Dieras V, Kalla S, Giaccetti S, Cvitkovic E, Aussel JP, Azli N, Riva A, Poullart P, Misser JL (1996) Docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer: a phase I dose rinding study. Proc Am Assoc Clin Oncol 15:148
3. Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M (1986) Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of Adriamycin and its metabolites in cancer patients. Cancer Chemother Pharmacol 17:80-84
4. Drori S, Eytan GD, Assaraf YG (1995) Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228: 1020-1029
5. Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS (1995) Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 319:309-315
6. Ellis AG, Crinis NA, Webster LK (1996) Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol 38:81-87
7. Friche E, Jensen PB, Sehested M, Demant EJF, Nissen NN (1990) The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 2:297-303
8. Gianni L, Locatelli A, Vigano L, Capri G, Giani A, Munzone E, Tarenzi E, Fulfaro F, Bonadonna G (1995) Order of administration and pharmacokinetics of paclitaxel by 3 h infusion and doxorubicin by iv bolus. Proc Am Soc Clin Oncol 14: 169
9. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699
10. Harrison SD, Cusie AM, McAfee SM (1984) Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume. Eur J Cancer 17:387-389
11. Hill BT, Whelan RDH, Shellard SA, McLean S, Hosking LK (1994) Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12: 169-182
12. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN (1996) Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721
13. Rischin D, Millward M, Webster L, Tinnelly K, Toner G, Bishop J, Linsenmeyer M, Woodcock D (1994) Phase I trial of Cremophor EL and doxorubicin in patients with advanced cancer. Anticancer Drugs 5 [Suppl 1]:43
14. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF (1996) Cremophor pharmacokinetics in patients receiving 3, 6 and 24 hour infusions of paclitaxel. J Natl Cancer Inst 88:1297-1301
15. Schuurhuis GJ, Broxterman HJ, Pinedo HM, Heijningen HM van, Kalken CK van, Vermorken JB, Spoelstra EC, Lankelma J (1990) The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer 62:591-594
16. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D (1993) Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistance phenotype. J Natl Cancer Inst 85:1685-1690
17. Webster LK, Cosson EJ, Stokes KH, Millward MJ (1996) Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73:522-524
18. Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I (1990) Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50:4199-4203
19. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH (1992) Reversal of multidrug resistance by surfactants. Br J Cancer 66:62-68